Medscape is available in 5 Language Editions – Choose your Edition here.


Capillary Hemangioma Treatment & Management

  • Author: Stuart Seiff, MD, FACS; Chief Editor: Hampton Roy, Sr, MD  more...
Updated: Oct 06, 2015

Medical Care

The indications for treatment can be divided into systemic, ophthalmic, and dermatologic reasons. Systemic reasons for intervention include congestive heart failure, thrombocytopenia, hemolytic anemia, and nasopharyngeal obstruction.[5] Ophthalmic indications for intervention include occlusion of the visual axis, optic nerve compression, severe proptosis, and anisometropia.[6, 7] Dermatologic indications for intervention include maceration and erosion of the epidermis, infection, and cosmetic disfigurement.


The first-line treatment of capillary hemangiomas is simple observation. Since most of these lesions regress on their own, there is no need to intervene unless one of the above criteria is met.[8]

Corticosteroid therapy

Corticosteroids, in various formulations, also have been used in the treatment of capillary hemangiomas.[9, 10, 11, 12, 13, 14, 15, 16, 17]

Topical steroid therapy

Topical steroid formulations, such as clobetasol propionate cream, can be applied topically to the lesion. The response to these treatments, even with the strongest corticosteroid formulations, is slower than other methods because several weeks are required to obtain a response.

Complications include dermal atrophy, pigmentary changes in the skin, and dermatitis, as well as less common ophthalmic complications, such as elevated intraocular pressure and cataract formation. Systemic absorption also can occur.

Overall, this modality is not appropriate for vision-threatening lesions.

Injectable steroid therapy

Injectable steroid formulations also are used in the treatment of these lesions.

Endothelial cell sensitization to catecholamines is the mechanism by which intralesional corticosteroids exert their effects. Although there may be a period of temporary enlargement, blanching usually is noted within 2-3 days and involution is seen by 2-4 weeks. Their effectiveness is most pronounced 2 weeks after injection but can be seen up to 2 months later. The overall success rate for this intervention is 75%.

Risks of injection include lid necrosis, depigmentation, and fat necrosis. The most disconcerting adverse effect concerns reports of central retinal artery occlusion following the intralesional injection of corticosteroids. Although the precise pathogenesis is uncertain, some suggest it may be related to anomalous vessels. A technically slower injection of corticosteroid or a smaller volume of solution may lessen the risk.[18, 19, 20]

Steroid injections can be repeated, but, ideally, they should be separated in time by 2-3 months to allow for maximum benefit to be seen. Adrenal suppression after cutaneous steroid injections has been reported.

Systemic corticosteroid therapy

Systemic corticosteroids are used for amblyogenic life-threatening lesions.

An excellent response rate can be expected in 30% of patients, a questionable response in 40%, and no response in 30% when systemic corticosteroids are used under close observation. The response may be quite dramatic within the first 2 weeks, and the effect may last from 1-4 months. Doses of 2-3 mg/kg may be necessary for up to several months.

Complications of systemic therapy with corticosteroids include Cushingoid changes, personality changes, gastrointestinal irritation, oral candidiasis, delayed growth, diabetes, hypertension, and rebound growth of hemangiomas on cessation.

Interferon alfa-2a therapy

Interferon alfa-2a has emerged as a new modality to combat the life-threatening and vision-threatening hemangiomas of infancy that are resistant to steroid treatment.[21] While it has potent effects on these lesions, it is commonly associated with adverse effects of varying severity.

Interferon alfa-2a exerts its effect by preventing endothelial cell migration in capillary hemangiomas. Authors have shown significant tumor regression after treatment with interferon.

Unfortunately, adverse effects from treatment may have somewhat dampened the initial excitement with this treatment. Adverse effects include fever, chills, arthralgias, and retinal vasculopathy. Of more significance, the incidence of spastic diplegia has been as high as 20% in some reports, leading some to reevaluate the benefits of its use. The long-term effects of interferon on the developing brain are unknown.

Propranolol therapy

Systemic propranolol has been added to the scope of treatment modalities available to patients with hemangiomas.

The literature surrounding this management option largely consists of anecdotal case reports, but an article by Al Dhaybi et al describes great success with oral propranolol, discontinued in only 1 of 18 patients due to side effects.[22] A reduction occurred in both radiographic volume and amblyogenic astigmatism.

A study by Missoi et al showed a 33% reduction in astigmatism and a 39% reduction in surface area in 17 children who were treated over a median duration of 6.8 months, suggesting that early intervention with propranolol is also effective for the treatment and prevention of visual acuity loss associated with periocular infantile hemangiomas.[23]

Propranolol has been suggested to be effective in reducing the size of juvenile hemangiomas, and, for patients who meet criteria for treatment of these lesions, it is worth consideration. The treatment does have potential complications, particularly cardiac, and patients need to be monitored closely.[24] It is highly recommended that the medication is administered and monitored for dose titration and systemic side effects by a pediatrician or pediatric cardiologist.

Timolol therapy

Topical timolol has been shown to be effective for localized and superficial hemangiomas.[25, 26, 27] Timolol may also be effective for larger, deeper lesions.[28]


Surgical Care

Laser surgery has been attempted to ameliorate capillary hemangiomas but is still controversial. The hemostatic effects of the carbon dioxide laser have been used with success to surgically remove these lesions. Other lasers used include the argon laser and the Nd:YAG laser. The pulsed dye laser is only effective for very superficial lesions; its mechanism of action is too slow for sight-threatening hemangiomas. Overall, variable results have been seen with various laser modalities, and the risks of scarring and ulceration often deter its use.

Incisional surgical techniques also have had variable success. Surgical ligation of the hemangiomas produces equivocal results. Vascular embolization of the lesions should be used for large extraorbital hemangiomas only. Primary excision also has been advocated for infantile hemangiomas. Early surgical intervention can be considered as a primary treatment option in selected, isolated capillary hemangiomas without a significant cutaneous component. Surgery can provide definitive early treatment and prevent astigmatism and occlusion-related amblyopia.[29, 30]



Consultations with a pediatrician may be necessary to monitor for the systemic adverse effects if prednisone is used or if there is suspicion of systemic involvement.

Pediatric dermatologists may have particular expertise in the various treatment options available.

Contributor Information and Disclosures

Stuart Seiff, MD, FACS Emeritus Professor of Ophthalmology, University of California, San Francisco, School of Medicine; Chief, Department of Ophthalmology, San Francisco General Hospital; Consultant, Oculofacial and Aesthetic Plastic Surgery, California Pacific Medical Center and Mills Peninsula Medical Center

Stuart Seiff, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American Society of Ophthalmic Plastic and Reconstructive Surgery, California Medical Association

Disclosure: Nothing to disclose.


Dan D DeAngelis, MD, FRCSC Assistant Professor of Ophthalmic Plastic and Reconstructive Surgery, Department of Ophthalmology and Vision Sciences, University of Toronto Faculty of Medicine; Ophthalmologist, Department of Ophthalmology and Vision Sciences, Hospital for Sick Children

Dan D DeAngelis, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Society of Ophthalmic Plastic and Reconstructive Surgery, California Medical Association, Canadian Medical Association, Canadian Ophthalmological Society, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Susan Carter, MD Clinical Associate Professor of Ophthalmology, Institute of Ophthalmology and Visual Science, New Jersey Medical School

Susan Carter, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Ophthalmic Plastic and Reconstructive Surgery

Disclosure: Nothing to disclose.

Orin M Zwick, MD Oculoplastic Surgeon, Chesapeake Eye Care and Laser Center

Orin M Zwick, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Brian A Phillpotts, MD, MD 

Brian A Phillpotts, MD, MD is a member of the following medical societies: American Academy of Ophthalmology, American Diabetes Association, American Medical Association, National Medical Association

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the assistance of Ryan I Huffman, MD, with the literature review and referencing for this article.

  1. Haik BG, Karcioglu ZA, Gordon RA, et al. Capillary hemangioma (infantile periocular hemangioma). Surv Ophthalmol. 1994 Mar-Apr. 38(5):399-426. [Medline].

  2. Rosca TI, Pop MI, Curca M, et al. Vascular tumors in the orbit--capillary and cavernous hemangiomas. Ann Diagn Pathol. 2006 Feb. 10(1):13-19. [Medline].

  3. Kavanagh EC, Heran MK, Peleg A, et al. Imaging of the natural history of an orbital capillary hemangioma. Orbit. 2006 Mar. 25(1):69-72. [Medline].

  4. Fernández-Vega Cueto L, Tresserra F, de la Paz MF. De novo growth of a capillary hemangioma of the conjunctiva. Arch Soc Esp Oftalmol. 2012 Dec 20. [Medline].

  5. Hernandez JA, Chia A, Quah BL, Seah LL. Periocular capillary hemangioma: management practices in recent years. Clin Ophthalmol. 2013. 7:1227-32. [Medline]. [Full Text].

  6. Weiss AH, Kelly JP. Reappraisal of astigmatism induced by periocular capillary hemangioma and treatment with intralesional corticosteroid injection. Ophthalmology. 2008 Feb. 115(2):390-397.e1. [Medline].

  7. Goggin M. Astigmatism and periocular hemangioma. Ophthalmology. 2008 Oct. 115(10):1854-5; author reply 1855. [Medline].

  8. Wittenberg L, Ma P. Treatment of a von Hippel-Lindau retinal capillary hemangioma with photodynamic therapy. Can J Ophthalmol. 2008 Oct. 43(5):605-6. [Medline].

  9. Assaf A, Nasr A, Johnson T. Corticosteroids in the management of adnexal hemangiomas in infancy and childhood. Ann Ophthalmol. 1992 Jan. 24(1):12-8. [Medline].

  10. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999 Nov. 104(6):1616-23. [Medline].

  11. Cruz OA, Zarnegar SR, Myers SE. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology. 1995 Dec. 102(12):2012-5. [Medline].

  12. Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus. 1994 May-Jun. 31(3):153-6. [Medline].

  13. Kushner BJ. Intralesional corticosteroid injection for infantile adnexal hemangioma. Am J Ophthalmol. 1982 Apr. 93(4):496-506. [Medline].

  14. O'Keefe M, Lanigan B, Byrne SA. Capillary haemangioma of the eyelids and orbit: a clinical review of the safety and efficacy of intralesional steroid. Acta Ophthalmol Scand. 2003 Jun. 81(3):294-8. [Medline].

  15. Friling R, Axer-Siegel R, Ben-Amitai D, et al. Intralesional and sub-Tenon's infusion of corticosteroids for treatment of refractory periorbital and orbital capillary haemangioma. Eye. 2008 Nov 7. [Medline].

  16. Thoumazet F, Léauté-Labrèze C, Colin J, Mortemousque B. Efficacy of systemic propranolol for severe infantile haemangioma of the orbit and eyelid: a case study of eight patients. Br J Ophthalmol. 2012 Mar. 96(3):370-4. [Medline].

  17. Aletaha M, Salour H, Bagheri A, Raffati N, Amouhashemi N. Successful treatment of orbital hemangioma with propranolol in a 5-year-old girl. Orbit. 2012 Feb. 31(1):18-20. [Medline].

  18. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg. 1986 Apr. 17(4):229-31. [Medline].

  19. Weiss AH. Adrenal suppression after corticosteroid injection of periocular hemangiomas. Am J Ophthalmol. 1989 May 15. 107(5):518-22. [Medline].

  20. Deboer MD, Boston BA. Failure-to-thrive in an infant following injection of capillary hemangioma with triamcinolone acetonide. Clin Pediatr (Phila). 2008 Apr. 47(3):296-9. [Medline].

  21. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998 Mar. 132(3 Pt 1):527-30. [Medline].

  22. Al Dhaybi R, Superstein R, Milet A, Powell J, Dubois J, McCuaig C, et al. Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. Ophthalmology. 2011 Jun. 118(6):1184-8. [Medline].

  23. Missoi TG, Lueder GT, Gilbertson K, Bayliss SJ. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol. 2011 Jul. 129(7):899-903. [Medline].

  24. Fridman G, Grieser E, Hill R, Khuddus N, Bersani T, Slonim C. Propranolol for the treatment of orbital infantile hemangiomas. Ophthal Plast Reconstr Surg. 2011 May-Jun. 27(3):190-4. [Medline].

  25. Ni N, Guo S, Langer P. Current concepts in the management of periocular infantile (capillary) hemangioma. Curr Opin Ophthalmol. 2011 Sep. 22 (5):419-25. [Medline].

  26. Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol. 2011 Mar. 129 (3):377-9. [Medline].

  27. Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol. 2010 Feb. 128 (2):255-6. [Medline].

  28. Xue K, Hildebrand GD. Deep periocular infantile capillary hemangiomas responding to topical application of timolol maleate, 0.5%, drops. JAMA Ophthalmol. 2013 Sep. 131 (9):1246-8. [Medline].

  29. Deans RM, Harris GJ, Kivlin JD. Surgical dissection of capillary hemangiomas. An alternative to intralesional corticosteroids. Arch Ophthalmol. 1992 Dec. 110(12):1743-7. [Medline].

  30. Slaughter K, Sullivan T, Boulton J, et al. Early surgical intervention as definitive treatment for ocular adnexal capillary haemangioma. Clin Experiment Ophthalmol. 2003 Oct. 31(5):418-23. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.